KR20240144442A - 나노입자 조성물에 대한 바이오마커 - Google Patents

나노입자 조성물에 대한 바이오마커 Download PDF

Info

Publication number
KR20240144442A
KR20240144442A KR1020247031052A KR20247031052A KR20240144442A KR 20240144442 A KR20240144442 A KR 20240144442A KR 1020247031052 A KR1020247031052 A KR 1020247031052A KR 20247031052 A KR20247031052 A KR 20247031052A KR 20240144442 A KR20240144442 A KR 20240144442A
Authority
KR
South Korea
Prior art keywords
mtor
cancer
abnormality
activation
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020247031052A
Other languages
English (en)
Korean (ko)
Inventor
네일 피. 데사이
Original Assignee
아브락시스 바이오사이언스, 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아브락시스 바이오사이언스, 엘엘씨 filed Critical 아브락시스 바이오사이언스, 엘엘씨
Publication of KR20240144442A publication Critical patent/KR20240144442A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020247031052A 2015-06-29 2016-06-29 나노입자 조성물에 대한 바이오마커 Ceased KR20240144442A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562186309P 2015-06-29 2015-06-29
US62/186,309 2015-06-29
PCT/US2016/040196 WO2017004264A1 (en) 2015-06-29 2016-06-29 Biomarkers for nanoparticle compositions
KR1020187002292A KR102708679B1 (ko) 2015-06-29 2016-06-29 나노입자 조성물에 대한 바이오마커

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187002292A Division KR102708679B1 (ko) 2015-06-29 2016-06-29 나노입자 조성물에 대한 바이오마커

Publications (1)

Publication Number Publication Date
KR20240144442A true KR20240144442A (ko) 2024-10-02

Family

ID=57609078

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020247031052A Ceased KR20240144442A (ko) 2015-06-29 2016-06-29 나노입자 조성물에 대한 바이오마커
KR1020187002292A Active KR102708679B1 (ko) 2015-06-29 2016-06-29 나노입자 조성물에 대한 바이오마커

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020187002292A Active KR102708679B1 (ko) 2015-06-29 2016-06-29 나노입자 조성물에 대한 바이오마커

Country Status (10)

Country Link
US (3) US20180177771A1 (enExample)
EP (1) EP3313381A4 (enExample)
JP (4) JP2018527308A (enExample)
KR (2) KR20240144442A (enExample)
AU (3) AU2016285727B9 (enExample)
CA (1) CA2990703C (enExample)
HK (1) HK1254398A1 (enExample)
IL (2) IL256326B2 (enExample)
MX (2) MX2017016519A (enExample)
WO (1) WO2017004264A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2700074T3 (es) 2006-12-14 2019-02-13 Abraxis Bioscience Llc Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano
RS59896B1 (sr) 2009-04-15 2020-03-31 Abraxis Bioscience Llc Kompozicije nanočestica bez priona i postupci povezani sa njima
BR112012024590A2 (pt) 2010-03-29 2016-05-31 Abraxis Bioscience Inc métodos de reforço da liberação de fármaco e da eficácia de agentes terapêuticos
KR102108959B1 (ko) 2011-04-28 2020-05-11 아브락시스 바이오사이언스, 엘엘씨 나노입자 조성물의 혈관내 전달 및 그의 용도
WO2013090634A1 (en) 2011-12-14 2013-06-20 Abraxis Bioscience, Llc Use of polymeric excipients for lyophilization or freezing of particles
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
EP3698784A1 (en) 2013-03-12 2020-08-26 Abraxis BioScience, LLC Methods of treating lung cancer
NZ630213A (en) 2013-03-14 2017-05-26 Abraxis Bioscience Llc Methods of treating bladder cancer
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
CN116473964A (zh) 2015-06-29 2023-07-25 阿布拉科斯生物科学有限公司 治疗上皮样细胞肿瘤的方法
WO2019140257A1 (en) * 2018-01-11 2019-07-18 Beth Israel Deaconess Medical Center, Inc. Compositions and methods for characterizing and treating prostate cancer
RU2020134124A (ru) * 2018-03-20 2022-04-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи СПОСОБЫ ЛЕЧЕНИЯ НАРУШЕНИЙ ЦЕНТРАЛЬНОЙ НЕРВНОЙ СИСТЕМЫ ПУТЕМ ВВЕДЕНИЯ СОДЕРЖАЩИХ ИНГИБИТОР mTOR И АЛЬБУМИН НАНОЧАСТИЦ
BR112020023431A2 (pt) * 2018-05-22 2021-02-23 Abraxis Bioscience, Llc métodos e composições para tratamento de hipertensão pulmonar
CN111187834B (zh) * 2019-01-08 2021-01-22 中国科学院上海营养与健康研究所 胃肠道间质瘤的靶点depdc5及其在诊断和治疗中的应用
EP3941551A4 (en) * 2019-03-19 2023-01-18 Abraxis BioScience, LLC SUBCUTANEOUS ADMINISTRATION OF NANOPARTICLES WITH AN MTOR INHIBITOR AND ALBUMIN FOR THE TREATMENT OF DISEASES
CA3158764A1 (en) 2019-10-28 2021-05-06 Abraxis Bioscience, Llc Pharmaceutical compositions of albumin and rapamycin
BR112022009018A2 (pt) * 2019-11-11 2022-10-11 Abraxis Bioscience Llc Biomarcadores para composições de nanopartícula
AU2021358768A1 (en) * 2020-10-06 2023-05-18 The Regents Of The University Of Colorado, A Body Corporate Subject-specific treatments for venetoclax-resistant acute myeloid leukemia
WO2022186673A1 (ko) * 2021-03-05 2022-09-09 전남대학교산학협력단 차세대 염기서열분석 기반 표적유전자 rna 염기서열 분석 패널 및 분석알고리즘
WO2024215799A1 (en) * 2023-04-11 2024-10-17 Leapfrog Bio, Inc. Pi3k inhibitors for the treatment of cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0808635B1 (pt) * 2007-03-07 2022-06-07 Abraxis Bioscience, Llc Uso de uma composição farmacêutica compreendendo nanopartículas que compreendem rapamicina ou um seu derivado e uma proteína veículo, composição para uso em um método de tratamento de câncer em um indivíduo, forma de dosagem unitária para o referido tratamento, e kit
MY188911A (en) * 2010-06-02 2022-01-13 Abraxis Bioscience Llc Methods of treating bladder cancer
BR112013016708B1 (pt) * 2010-12-30 2021-08-17 Foundation Medicine, Inc Otimização de análise multigene de amostras de tumor
NZ630213A (en) * 2013-03-14 2017-05-26 Abraxis Bioscience Llc Methods of treating bladder cancer
EP2971122B1 (en) * 2013-03-15 2020-08-26 Memorial Sloan Kettering Cancer Center Biomarkers for response to rapamycin analogs
HK1247093A1 (zh) * 2015-06-29 2018-09-21 阿布拉科斯生物科学有限公司 使用纳米颗粒mtor抑制剂联合疗法治疗实体瘤的方法

Also Published As

Publication number Publication date
IL256326B1 (en) 2024-05-01
AU2021290200A1 (en) 2022-01-20
EP3313381A1 (en) 2018-05-02
MX2017016519A (es) 2018-08-16
KR20180019230A (ko) 2018-02-23
US20230080409A1 (en) 2023-03-16
MX2023013010A (es) 2023-11-15
EP3313381A4 (en) 2019-02-27
AU2016285727B2 (en) 2021-09-23
JP2023071656A (ja) 2023-05-23
US20180177771A1 (en) 2018-06-28
JP2025097987A (ja) 2025-07-01
JP2018527308A (ja) 2018-09-20
US20250152563A1 (en) 2025-05-15
AU2016285727B9 (en) 2021-09-30
IL312318A (en) 2024-06-01
JP2021169457A (ja) 2021-10-28
AU2016285727A1 (en) 2018-02-01
CA2990703A1 (en) 2017-01-05
IL256326B2 (en) 2024-09-01
AU2024204661A1 (en) 2024-07-25
CA2990703C (en) 2024-04-30
HK1254398A1 (zh) 2019-07-19
IL256326A (en) 2018-02-28
AU2021290200B2 (en) 2024-05-02
KR102708679B1 (ko) 2024-09-24
WO2017004264A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
AU2021290200B2 (en) Biomarkers for nanoparticle compositions
JP7738612B2 (ja) 類上皮細胞腫瘍を処置する方法
JP2018527308A5 (enExample)
US20240009323A1 (en) Methods of treating colon cancer using nanoparticle mtor inhibitor combination therapy
HK40074948A (en) Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
HK40074948B (en) Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
HK1247094B (en) Nanoparticles comprising sirolimus and an albumin for use in treating epithelioid cell tumors
EA045904B1 (ru) Способы лечения эпителиоидноклеточных опухолей

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240913

Application number text: 1020187002292

Filing date: 20180124

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241011

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20241211

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20250613

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D